首頁 > 市場調查報告書 > 製藥

循環系統

市場調查報告書

商品編碼

1425110

心房中膈缺損症市場 – 2024 年至 2029 年預測

Atrial Septal Defect Market - Forecasts from 2024 to 2029

出版日期: 2024年01月25日 | 出版商:

Knowledge Sourcing Intelligence | 英文 146 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

2022年心房中膈缺損症市場規模為24.31億美元。

心房中膈缺損症（ASD）是最常見的先天性心臟疾病（CHD）之一，也是成人最常見的先天性心臟病。在過去的幾十年裡，自閉症譜系障礙的治療方法發生了典範轉移。由於經導管治療方法和器械的發展和完善，器械封堵術治療自閉症譜系障礙（ASD）已顯示出良好的療效，並且與手術相比，降低了併發症的發生率，因此目前已應用於大多數自閉症譜系治療方法。的選擇在

心房中膈缺損症市場促進因素

由於患者和醫療保健專業人員越來越偏好微創手術，心房中膈缺損症產業預計將成長。這些創新侵入性較小，可縮短住院時間、加速復原時間並減少疤痕。各種技術進步正在推動產品創新，從而提高病患安全和臨床結果。此外，醫療費用的增加和社會對 ASD 治療意識的提高也是推動心房中膈缺損症市場成長的因素。

中風盛行率增加

中風被認為是全球第二大死因。例如，根據美國疾病管制與預防中心美國的數據，六分之一的心血管疾病死亡病例是中風造成的。在美國，每 40 秒就會發生一次中風，每 3 分 14 秒就會奪走一人生命。美國每年有超過 795,000 人中風。其中約 61 萬例為新發或首次中風，約 185,000 例（幾乎四分之一）發生在已患過中風的患者中。缺血性中風（即流向大腦的血液受阻）約佔所有中風的 87%。這一成長預計將有助於擴大心房中膈缺損症行業的市場佔有率。

提高對不同類型心房中膈缺損症的認知

各種心房中膈缺損症的知識的開拓在市場的發展中起著關鍵作用。當繼發孔間隔未完全閉塞繼發孔間隔或心房頂原發間隔發生顯著吸收時，就會發生繼發孔間隔缺損。心房中隔缺損是第三常見的心房中膈缺損症，是由於房間隔無法與心內膜墊連接而引起的。心肌的靜脈回流由構成冠狀竇的靜脈代表，冠狀竇是沿著左心房和左心室之間的凹槽運行的動脈。在三尖瓣的隔葉上方，它經常排放右心房的底部。

手術閉合治療預計將佔據最大的市場佔有率

手術閉合療法預計將顯著增加，主要是由於其高成功率和長期耐用性。心臟直視手術使用補片或縫合來修復缺損並閉合心臟中的孔。對於患有多種異常或潛在心臟病的患者，建議進行手術閉合。手術閉合被認為是治療大型複雜自閉症譜系障礙的黃金標準，適合所有年齡層的患者。此外，基於導管的閉合技術預計將佔據第二大市場佔有率。在這種治療方法中，導管穿過鼠蹊部的小切口進入心臟。

改善醫療團隊的成果

房間隔異常患者需要一個由患者小兒科、基層醫療醫生和執業護士積極參與的跨專業團隊，以改善醫療團隊的治療結果。基層醫療醫生通常會在將患者轉診給循環系統之前對 ASD 進行初步診斷。循環系統定期對心房中膈缺損症的成人和兒童進行隨訪，以檢查心臟的解剖結構、功能和血流動力學狀態。

在亞太地區，心房中膈缺損症市場預計將穩定成長。

由於先天性心臟疾病率上升以及 ASD 治療需求不斷成長，預計亞太地區的心房中膈缺損症市場將在預測期內成長。推動亞太地區心房中膈缺損症市場成長的主要因素是醫療旅遊、醫療基礎設施的增加以及醫療保健領域投資的增加。在亞太地區，印度和中國由於人口眾多且可支配收入不斷增加，預計將佔據最大的市場佔有率。

政府對心房中膈缺損症市場的監管

美國食品藥物管理局(FDA) 透過設備和放射健康中心 (CDRH)監督用於識別和治療 ASD 的醫療設備。
歐盟 (EU) 根據醫療設備指令 93/42/EEC 對用於 ASD 診斷和治療的醫療設備進行監管。
世界衛生組織《菸草控制框架公約》(FCTC) 要求各國政府制定法規，減少菸草使用並保護公共衛生免受吸菸的有害影響。

心房中膈缺損症產品

Occlutech Figulla Flex II ASD 封堵器，用於 ASD 封堵的第三代 Occlutech 裝置，Figulla Flex II ASD 封堵器（FSO，Occlutech GmbH，耶拿，德國）採用軟性鈦氧化物塗層鎳鈦諾網膜和與ASO 相同的雙盤。它有一個結構。
Nit-Occlud ASD-R，Nit-Occlud ASD-R (NOA-R) 是德國科隆 pfm Medical 製造的雙盤、自膨脹、自定心裝置；它與其他硝基網膜裝置有顯著不同。它的特點。

One of the most prevalent congenital heart diseases (CHDs) and the most prevalent CHD in adults is atrial septal defect (ASD). Over the past few decades, the therapy approach for ASD has undergone a paradigm change. Device closure of ASD is currently regarded as the treatment of choice in the majority of patients with secundum ASD, displaying great effectiveness as well as a decreased complication rate compared to surgery, as a consequence of the development and refinement of transcatheter treatment methods and devices.

Driving factors for the atrial septal defect market

The atrial septal defect industry is anticipated to grow due to the rising preference for minimally invasive procedures by patients and healthcare professionals. These innovations are less invasive and offer shorter hospital stays, quicker recuperation times, and minimum scarring. Various technological advancements have led to product innovations that enhance patient safety and clinical outcomes. Moreover, the increasing healthcare costs and growing public awareness of ASD treatments are some other factors fueling the atrial septal defect market growth.

Increasing prevalence of strokes

Stroke is considered the second leading cause of death worldwide. For instance, according to the Centers for Disease Control and Prevention in 2021, stroke was the cause of 1 in 6 fatalities from cardiovascular disease. A stroke occurs in the United States every 40 seconds and claims the life of a person every 3 minutes and 14 seconds. Over 795,000 people in the US experience a stroke each year. Of them, about 610,000 are new or first strokes, and nearly one in four strokes, or around 185,000, occur in persons who have already had a stroke. Ischemic strokes, in which blood flow to the brain is interrupted, account for around 87% of all strokes. This growth will contribute to the growing market share for the atrial septal defect industry.

Rising awareness of different types of atrial septal defects

Growth in knowledge about various atrial septal defects plays a key role in the development of the market. Ostium secundum defect develops when the septum secundum does not completely occlude the ostium secundum or when there is greater reabsorption of the septum primum in the atrium's ceiling. Ostium primum defect is an atrial septal defect, which is the third most frequent, resulting from the septum primum's inability to merge with the endocardial cushions. Heart muscle's venous return is represented by the veins that make up the coronary sinus, an artery that runs along the groove between the left atrium and left ventricle. Above the septal leaflet of the tricuspid valve, it often drains onto the right atrium's floor.

Surgical closure treatment is anticipated to hold the maximum market share

Surgical closure treatment is predicted to rise significantly mainly due to its high success rate and long-term durability. During open-heart surgery, a patch or suture is used to patch up the defect and the hole in the heart is closed. Surgical closures are recommended for patients who have multiple abnormalities or any underlying heart condition. It is regarded as the gold standard for treating large and complex ASDs and is suitable for patients of all ages. Furthermore, catheter-based closures are anticipated to hold the second-largest atrial septal defect market share. This treatment entails a catheter threaded up to the heart through a tiny incision of the groin.

Enhancing healthcare team outcomes

Patients with atrial septal abnormalities require an interprofessional team with significant participation from the patient's paediatrician, primary care doctor, and nurse practitioner to improve healthcare team outcomes. The primary care physician often makes the first diagnosis of ASD before referring the patient to the cardiologist. Cardiologists regularly follow up with patients who have atrial septal defects in adults and children to check on the heart's anatomy, function, and hemodynamic condition.

In Asia Pacific, it is projected that the atrial septal defect market will grow steadily.

The atrial septal defect market is anticipated to grow in Asia Pacific during the projected period due to the rising prevalence of congenital cardiac conditions and the increasing need for ASD therapy. Medical tourism, an increase in healthcare infrastructure, and increased investment in the healthcare sector are the key factors fueling the atrial septal defect market growth in the Asia Pacific region. India and China are anticipated to hold the maximum market share in the Asia Pacific region owing to their vast population and growing disposable income.

Government regulations for the atrial septal defect market

Through its Centre for Devices and Radiological Health (CDRH), the Food and Drug Administration (FDA) in the United States oversees medical devices used to identify and treat ASDs.
Following the Medical Device Directive 93/42/EEC, the European Union has defined regulations for medical devices used in the diagnosis and treatment of ASDs.
Governments are urged by the Framework Convention on Tobacco Control (FCTC) of the WHO to cut back on tobacco use and create regulations to safeguard the public's health from the negative effects of smoking.

Atrial Septal Defect Products

Occlutech Figulla Flex II ASD Occluder, The third generation Occlutech device for ASD closure, the Figulla Flex II ASD Occluder (FSO, Occlutech GmbH, Jena, Germany), has a flexible titanium-oxide coated nitinol mesh and a double-disk construction identical to the ASO.
Nit-Occlud ASD-R, The Nit-Occlud ASD-R (NOA-R) is a double-disk, self-expandable, self-centering device made by pfm Medical in Cologne, Germany, although it differs significantly from other nitrol-mesh devices in terms of its design features.

Market Key Developments

In August 2022, InnAVasc Medical, Inc., a privately held medical technology company, was acquired by W. L. Gore & Associates, Inc. (Gore), a global material science company committed to transforming industries and improving lives.
In July 2022, the launch of Qosina's AseptiQuik STC line of Steam-Thru connections was announced. The new line incorporates both the Steam-Thru II Steam-in-Place connector and the AseptiQuik sterile connector, giving manufacturers flexibility between hybrid stainless steel and single-use processing equipment.

Segmentation:

By Symptoms

Frequent Respiratory Infections
Swelling Legs and Feet
Heart Palpitations
Fatigue

By Diagnosis

Chest X-ray
Electrocardiogram

By End-User

Hospitals
Clinics
Others

By Geography

North America
United States
Canada
Mexico
South America
Brazil
Argentina
Others
Europe
United Kingdom
Germany
France
Spain
Others
Middle East and Africa
Saudi Arabia
UAE
Israel
Others
Asia Pacific
Japan
China
India
South Korea
Indonesia
Thailand
Others

1. INTRODUCTION

1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Market Segmentation
1.5. Currency
1.6. Assumptions
1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

2.1. Research Data
2.2. Assumptions

3. EXECUTIVE SUMMARY

3.1. Research Highlights

4. MARKET DYNAMICS

4.1. Market Drivers
4.2. Market Restraints
4.3. Porter's Five Force Analysis
- 4.3.1. Bargaining Power of Suppliers
- 4.3.2. Bargaining Power of Buyers
- 4.3.3. Threat of New Entrants
- 4.3.4. Threat of Substitutes
- 4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis

5. ATRIAL SEPTAL DEFECT MARKET, BY SYMPTOMS

5.1. Introduction
5.2. Frequent Respiratory Infections
5.3. Swelling Legs and Feet
5.4. Heart Palpitations
5.5. Fatigue

6. ATRIAL SEPTAL DEFECT MARKET, BY DIAGNOSIS

6.1. Introduction
6.2. Chest X-ray
6.3. Electrocardiogram

7. ATRIAL SEPTAL DEFECT MARKET, BY END-USER

7.1. Introduction
7.2. Hospitals
7.3. Clinics
7.4. Others

8. ATRIAL SEPTAL DEFECT MARKET, BY GEOGRAPHY

8.1. Introduction
8.2. North America
- 8.2.1. United States
- 8.2.2. Canada
- 8.2.3. Mexico
8.3. South America
- 8.3.1. Brazil
- 8.3.2. Argentina
- 8.3.3. Others
8.4. Europe
- 8.4.1. United Kingdom
- 8.4.2. Germany
- 8.4.3. France
- 8.4.4. Spain
- 8.4.5. Others
8.5. The Middle East and Africa
- 8.5.1. Saudi Arabia
- 8.5.2. UAE
- 8.5.3. Israel
- 8.5.4. Others
8.6. Asia Pacific
- 8.6.1. Japan
- 8.6.2. China
- 8.6.3. India
- 8.6.4. South Korea
- 8.6.5. Indonesia
- 8.6.6. Thailand
- 8.6.7. Others